New shot aims to tame severe skin rash
NCT ID NCT07399067
Summary
This study is testing whether a new injectable drug called IBI3002 can safely reduce the severity of moderate to severe atopic dermatitis (eczema). About 120 adults with eczema that hasn't responded well to creams will receive either IBI3002, an approved drug (dupilumab), or a placebo shot. Researchers will measure changes in skin rash and itchiness over 16 weeks to see if IBI3002 works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100192, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.